To include your compound in the COVID-19 Resource Center, submit it here.

Darzalex CASTOR data shine at ASCO

Data presented at the American Society of Clinical Oncology annual meeting revealed a reduced risk of disease progression and higher response rates among patients treated with Darzalex daratumumab plus Velcade bortezomib and dexamethasone vs.

Read the full 346 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE